What Primolut Depot Helps Manage

This medication is used to provide supportive care and symptom management in specific gynecological and obstetric contexts. It is primarily utilized for:

• Abnormal uterine bleeding: Addressing instances of heavy, prolonged, or unpredictable menstrual bleeding.
• Amenorrhea: Assisting in cases where expected monthly periods are absent.
• High-risk pregnancy support: Providing management in scenarios involving a history of recurrent miscarriage or risks of premature labor.

The treatment is used to stabilize symptoms that interfere with daily functioning and to provide support during periods of heightened physical distress. It is applied in clinical situations where supportive management is necessary to address conditions characterized by intense or fluctuating symptom patterns.

---

Quick Fact: Relief for Disruptive Symptom Patterns

This treatment addresses symptom clusters that may become intense, offering relief that contributes to improved comfort. By managing these fluctuations, it helps maintain a more steady state when symptoms would otherwise disrupt daily activities and well-being.

Primolut Depot (hydroxyprogesterone caproate) is a hormonal injection used to treat certain conditions, primarily related to menstrual cycle disorders and risk of recurrent miscarriage due to corpus luteum insufficiency. It is generally intended for non-pregnant women with specific diagnoses or for use in the first trimester of pregnancy only for conditions like habitual or threatened abortion, under strict medical guidance.

---

Who May Use Primolut Depot

Condition
Certain menstrual disorders (primary/secondary amenorrhea, dysfunctional uterine bleeding)
Threatened or habitual abortion where corpus luteum insufficiency is suspected
Advanced adenocarcinoma of the uterine corpus (Stage III or IV)

---

Who Should NOT Use Primolut Depot (Contraindications)

Primolut Depot is contraindicated for individuals with certain pre-existing conditions. You must not use this medication if you have or have had:

• Thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism).
• Active arterial or cardiovascular disease (e.g., history of myocardial infarction, stroke).
• Known or suspected hormone-dependent malignancies (like breast or genital cancer).
• Severe liver disease or liver tumors (benign or malignant).
• Undiagnosed abnormal vaginal bleeding (unrelated to pregnancy).
• Hypersensitivity (allergy) to hydroxyprogesterone caproate or its excipients.

Patients with conditions like diabetes, epilepsy, migraine, asthma, or depression require close medical supervision.

Official Interaction Profile: Regulatory Documentation

The formal regulatory documentation for Primolut Depot (hydroxyprogesterone caproate) addresses interactions based on the medicine's metabolic clearance pathway and specific pharmacodynamic effects. Notably, regulatory labeling states that no dedicated human in vivo drug-drug interaction studies were conducted.

Pharmacokinetic Interactions (Drug Exposure)

The medicine is primarily cleared through the Cytochrome P450 (CYP) 3A4 and CYP3A5 enzyme systems. Based on this established pathway, official statements indicate that co-administration with strong CYP3A enzyme modulators is expected to alter the medicine’s concentration:

• CYP3A Inhibitors: Expected to increase the systemic exposure (plasma levels) of Primolut Depot.
• CYP3A Inducers: Expected to decrease the systemic exposure of Primolut Depot.

Conversely, in vitro data documented in the labeling suggest the medicine itself has a minimal potential to inhibit numerous other CYP enzymes (including CYP2C8, CYP2D6, and CYP3A4), indicating a low risk of affecting the clearance of most co-administered medicines through this mechanism.

Pharmacodynamic and Condition-Specific Notes

Classification	Documentation
Pharmacodynamic Interaction	The medicine may cause a decrease in glucose tolerance, requiring consideration when co-administered with antidiabetic agents.
Population Constraint	Use is contraindicated in patients with active liver disease or liver tumors, which are conditions known to severely impair drug clearance and alter the metabolic interaction profile.
Contraindicated Combinations	No specific medicinal product combinations are formally prohibited due to drug-drug interaction risk.

Pharmacodynamics: Endometrial and Systemic Modulation

Primolut Depot functions as a sustained-release formulation delivering a synthetic progestogen, norethisterone enanthate. The active metabolite, norethisterone, acts as a progesterone receptor agonist. Upon systemic distribution, the compound selectively targets the nuclear progesterone receptors localized primarily within the endometrial tissue.

Receptor binding initiates a molecular cascade that modulates gene transcription. This modification promotes the development of a fully secretory and involuted endometrium, inducing morphological changes consistent with the luteal phase. Concurrently, the progestogen exerts control over the hypothalamic-pituitary-ovarian (HPO) axis via a negative feedback loop. This systemic feedback mechanism results in the suppression of pituitary gonadotropin secretion, specifically reducing the pulsatile release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), which prevents the preovulatory LH surge.

Primolut Depot, which contains hydroxyprogesterone caproate, is an injectable formulation administered by a healthcare professional. The drug's historical uses have included the management of certain gynecological disorders and, under previous accelerated approval in the United States, reducing the risk of recurrent preterm birth in women with a history of spontaneous preterm delivery and a singleton pregnancy.

General Administration

Administration is typically performed through a deep intramuscular injection, commonly into the upper outer quadrant of the gluteal muscle (buttock) or, for certain formulations of hydroxyprogesterone caproate, subcutaneously (under the skin).

• Do not self-administer this medication. The injection must be given by a trained healthcare provider.
• The injection site is rotated for each dose to minimize local reactions.
• Visually inspect the solution before use; it is usually clear and yellow. Do not use if particles are present or the solution is cloudy.

Dosage and Scheduling

Dosage and frequency depend entirely on the medical condition being treated and the specific formulation used. For example, in non-pregnant individuals, a single dose of 375 mg intramuscularly has been used to address dysfunctional uterine bleeding or amenorrhea. Conversely, the historical dosing for preterm birth prevention was 250 mg intramuscularly or 275 mg subcutaneously once every seven days, starting between 16 and 20 weeks of gestation and continuing until week 37.

It is crucial to adhere strictly to the schedule prescribed by your healthcare provider to achieve the intended therapeutic effect. If a dose is missed, contact your doctor immediately for instructions.

Research Evidence / Overview of Studies for Primolut Depot

This overview summarizes the type of research and key observations reported in official and peer-reviewed sources regarding the clinical evaluation of hydroxyprogesterone caproate (Primolut Depot), without offering any medical advice or instructions.

---

Evidence Regarding Recurrent Preterm Birth Prevention (Historical Research)

The use of this medicine was studied for individuals with a prior history of spontaneous preterm birth, a population that was studied for this medicine. This condition is characterized by fluctuating or episodic manifestations. The research base includes large-scale, international Randomized Controlled Trials (RCTs) and meta-analyses that explored this specific condition. These studies monitored individuals with a singleton pregnancy and a prior history of spontaneous preterm birth, starting treatment in the second trimester.

• Key Trial Designs and Primary Outcomes Examined

The studies were designed to evaluate primary endpoints related to the timing of delivery. Outcomes research examined included the rate of delivery before 37 weeks and before earlier gestational ages. Research also monitored composite neonatal health status, meaning they looked at a collection of outcomes related to the infant's health, such as respiratory status and mortality. Earlier sentinel trials reported measurements of delivery timing patterns. However, a subsequent, larger confirmatory trial reported no notable difference in delivery timing patterns compared to placebo. The findings across the major trials were inconsistent.

---

Evidence Regarding Menstrual Cycle Abnormalities

Research has also explored the use of this medicine in non-pregnant adult individuals facing conditions involving periods of heightened symptoms related to menstrual function, specifically amenorrhea (absence of periods) and abnormal uterine bleeding. The evidence for these established uses is primarily derived from historical clinical studies and observational cohorts. Modern, large-scale RCTs are limited for these indications.

• Focus of Historical Study Endpoints

The historical research examined outcomes related to systemic or functional imbalance. Studies monitored bleeding patterns for changes in dysfunctional bleeding, and they also observed the occurrence of withdrawal bleeding in those with amenorrhea. Further research examined the histological changes within the uterine lining to describe the changes observed with the progestogen. Research so far indicates that these outcomes were typically monitored over short-term, defined time intervals and describe group patterns, not personal outcomes.

---

Areas of Uncertainty and Research Gaps

A primary limitation is the inconsistency of findings between the major trials conducted for the recurrent preterm birth indication, leading to low certainty about its effect in that context. Furthermore, for the older gynecological uses, the evidence quality varies across studies, with a limited amount of contemporary, high-quality research available. Studies focusing on patient-reported outcomes describing perceived discomfort and the available data regarding long-term effects on menstrual health recurrence or functional quality of life following repeated treatment cycles is not fully established.

Key Studies & References

1. ACOG Practice Bulletin No. 130: Prediction and Prevention of Recurrent Preterm Birth
2. MedlinePlus: Hydroxyprogesterone

Common questions about Primolut Depot (FAQ)

Q: What is the main difference between Primolut Depot and Primolut N?

A: Regulatory documents indicate that Primolut Depot contains the progestogen Hydroxyprogesterone caproate and is given as a long-acting injection. Primolut N contains a different active ingredient, Norethisterone, and is typically an oral tablet. The distinction lies in the respective active chemical ingredients and the method of administration (injection for Depot, typically oral for N).

Q: How long does the effect of a Primolut Depot injection typically last?

A: According to the official product information, Primolut Depot is engineered as a depot injection in an oil base. This formulation allows for a slow, sustained release of the active ingredient over an extended duration. The intended duration of release depends on the medical condition being addressed and the specific schedule determined by a healthcare provider.

Q: Can Primolut Depot be used for fertility treatments?

A: Official documentation describes its use for specific gynecological disorders, such as the management of amenorrhea (absence of a period) and threatened or habitual abortion where corpus luteum insufficiency is suspected. Its documented uses relate to the management of specific gynecological disorders.

Q: Is it normal to feel pain at the injection site after getting Primolut Depot?

A: Injection site pain is listed in regulatory documents as a very common adverse reaction. This designation means that this effect is frequently reported by individuals receiving the medicine at the site where the injection was administered.

Q: Can Primolut Depot affect mood or cause emotional changes?

A: Official safety information lists depression as a possible adverse reaction to the medicine. Official documentation advises that patients with a history of clinical depression require careful monitoring while the medicine is being administered.

Q: Is Primolut Depot safe to use for women who have had blood clots in the past?

A: The medicine is contraindicated and should not be administered to individuals who have a current or historical diagnosis of blood clots (thromboembolic disorders). It is also contraindicated for those with severe arterial or cardiovascular diseases due to the known risks of vascular events.

Q: What types of bleeding issues is Primolut Depot used to manage?

A: Official indications include managing conditions such as primary or secondary amenorrhea (absence of periods) and abnormal uterine bleeding that is due to a hormonal imbalance. The medicine is intended to provide hormonal support to help stabilize the uterine lining.

Q: Does Primolut Depot contain estrogen?

A: No, Primolut Depot contains Hydroxyprogesterone caproate, the active ingredient. It is classified as a synthetic progestogen, which is a substance that mimics the biological activity of the hormone progesterone.

Q: What is the purpose of the 'Depot' part of the drug name?

A: The term 'Depot' in the name signifies that the medicine is formulated to be a long-acting injection. This characteristic allows the active ingredient to be slowly and continuously released into the body over an extended period following administration.

Q: Why is Primolut Depot given as an injection instead of a tablet?

A: The medication is formulated as a depot injection in an oil base, which is specifically designed for a slow, sustained release of the active substance. This formulation is designed to provide a slow, sustained release of the active ingredient, which helps achieve more consistent hormone levels over an extended duration compared to standard oral tablets.

Q: Can Primolut Depot be used in younger women (under 18)?

A: Official documentation for the injection indicates that it is not indicated for use in individuals younger than 16 years of age. Safety and effectiveness have not been fully established in this patient group.

Q: Are there special considerations for people with diabetes using Primolut Depot?

A: Official documents state that the medicine may cause a decrease in glucose tolerance. For this reason, official documentation advises that patients who are prediabetic or diabetic require careful monitoring by a healthcare provider while the medicine is being administered.

Q: Can Primolut Depot interact with common pain relievers like ibuprofen?

A: Official documentation does not name specific common pain relievers. However, the medicine is cleared from the body by specific CYP3A liver enzymes. Strong inhibitors or inducers of these enzymes, which may be present in other medicines, could potentially alter the concentration of Primolut Depot in the body.

Q: Do official documents mention any common vision changes associated with Primolut Depot?

A: Official warnings state that the medicine must be discontinued immediately if symptoms such as sudden loss of coordination or vision changes occur. These symptoms are listed because they can potentially be signs of a serious vascular event.

Q: Can Primolut Depot interact with herbal supplements?

A: The regulatory label advises individuals to discuss the use of all medicines, including prescription, nonprescription, over-the-counter (OTC) medicines, and herbal supplements, with their healthcare professional. This guidance is provided to help assess potential interactions.

Q: Does Primolut Depot have any reported interactions with alcohol?

A: The official interaction profile does not list a specific interaction with alcohol in regulatory documents. However, general regulatory guidance indicates that it is appropriate to discuss the consumption of alcohol with a healthcare professional while using any medication.

Q: What is the standard frequency of administration for Primolut Depot?

A: The dosage and frequency of administration for Primolut Depot depend entirely on the medical condition being treated. Examples cited in documentation range from a single dose for certain conditions to a weekly injection for others. The appropriate schedule is determined and prescribed by a healthcare provider based on the individual's needs.

Q: Why might a doctor switch a patient from an oral progestin to Primolut Depot?

A: The depot formulation is specifically engineered for a slow, sustained release of the active ingredient over an extended period. This design can provide a more consistent hormonal environment over time compared to oral formulations requiring frequent daily dosing.

Q: Can Primolut Depot be used in women who are breastfeeding?

A: Official labeling reports that detectable amounts of progestins have been found in the milk of nursing mothers. Studies have generally reported no documented adverse effects on the infant’s growth and development or on breastfeeding performance.

Q: What patient groups are specifically mentioned as needing close monitoring when using Primolut Depot?

A: Official documentation requires close monitoring for patients with a history of clinical depression. It also advises that treatment should be stopped if a patient experiences the onset or worsening of migraine or severe headaches.

Q: Are there specific instructions for the injection site care after receiving Primolut Depot?

A: Official documentation emphasizes that the injection must be given by a trained healthcare provider, and the injection site is typically rotated for each dose to help minimize local reactions. The focus is on professional administration and proper site rotation.

Q: What kind of studies have been done on the long-term effects of Primolut Depot?

A: Historical research has examined outcomes related to bleeding patterns over short-term, defined time intervals for gynecological uses. Official documents indicate that the evidence quality varies, and long-term data focusing on outcomes like recurrence or functional quality of life is not fully established.

Q: How is the effectiveness of Primolut Depot measured in clinical settings?

A: For established gynecological uses, historical research has typically monitored bleeding patterns for changes in dysfunctional bleeding. Studies have also observed the occurrence of withdrawal bleeding in those with amenorrhea to describe the measured effect of the progestogen.

Storage and Disposal Requirements for Primolut Depot

Primolut Depot (Hydroxyprogesterone Caproate Injection) must be stored according to strict regulatory conditions to ensure its stability.

Official Storage Conditions

The medicine requires storage at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be protected from light and must be kept in its original packaging. It is strictly required not to refrigerate or freeze the injection. Keep this medicine out of the sight and reach of children.

Stability and Disposal

For multi-dose vials, any unused portion must be discarded 5 weeks after the first use. Used needles, syringes, and vials must be immediately placed into a designated sharps disposal container according to local, regional, and national regulations. The product should not be disposed of in household waste or poured down a drain.